DC
SGMT icon

Diametric Capital’s Sagimet Biosciences SGMT Stock Holding History

Diametric Capital’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.5K Buy
+10,043
New +$56K 0.01% 452

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Diametric Capital's SGMT Position: Q1 2026 in Review

Diametric Capital opened a new position in Sagimet Biosciences (SGMT) in Q1 2026: 10,043 shares worth $52.5K. The stake represents 0.01% of the portfolio and ranks #452 among its holdings.

88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Diametric Capital held 10,043 shares of Sagimet Biosciences worth $52.5K as of Q1 2026.
  • Sagimet Biosciences was a new Diametric Capital position in Q1 2026.
  • Sagimet Biosciences made up 0.01% of Diametric Capital's portfolio in Q1 2026, its #452 holding.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Diametric Capital's 13F filing for Q1 2026, filed 15 May 2026.